Shire PLC (LON:SHP)‘s stock had its “outperform” rating restated by Royal Bank Of Canada in a research report issued on Friday, July 7th, MarketBeat Ratings reports.
Several other research firms have also commented on SHP. J P Morgan Chase & Co reissued an “overweight” rating and issued a GBX 6,000 ($79.15) price target on shares of Shire PLC in a research report on Monday, March 27th. Barclays PLC reissued an “overweight” rating and issued a GBX 6,300 ($83.10) price target on shares of Shire PLC in a research report on Monday, July 3rd. Liberum Capital reissued a “buy” rating and issued a GBX 5,500 ($72.55) price target on shares of Shire PLC in a research report on Monday, April 10th. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a research report on Wednesday, April 12th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a GBX 5,400 ($71.23) price target on shares of Shire PLC in a research report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Shire PLC presently has an average rating of “Buy” and an average price target of GBX 5,957.88 ($78.59).
Shire PLC (SHP) traded down 2.42% during midday trading on Friday, hitting GBX 4018.50. The stock had a trading volume of 3,621,641 shares. The stock’s market cap is GBX 36.33 billion. Shire PLC has a 52-week low of GBX 3,957.00 and a 52-week high of GBX 5,377.00. The company’s 50 day moving average price is GBX 4,283.27 and its 200-day moving average price is GBX 4,548.83.
ILLEGAL ACTIVITY NOTICE: “Shire PLC (SHP) Given Outperform Rating at Royal Bank Of Canada” was posted by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://baseballnewssource.com/markets/shire-plcs-shp-outperform-rating-reaffirmed-at-royal-bank-of-canada-updated-updated-updated/1169419.html.
In other news, insider Dominic Blakemore purchased 152 shares of the company’s stock in a transaction on Friday, June 30th. The shares were acquired at an average price of GBX 4,255 ($56.13) per share, for a total transaction of £6,467.60 ($8,531.33).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with our FREE daily email newsletter.